Public

Position Statements on the Use of Biosimilars in the Ministry of Health, Malaysia Healthcare Facilities

Date: 15 October 2023 - 5:21am

The increasing use of biological medicines including biosimilars in the Ministry of Health (MOH), Malaysia facilities warrants a suitable guidance document to ensure safe

English

#MedSafetyWeek 2022

During the annual #MedSafetyWeek global campaign, National Pharmaceutical Regulatory Agency (NPRA) collaborates with the Uppsala Monitoring Centre (UMC, the World Health Organisation (WHO) Collaborating Centre for International Drug Monitoring), medicines regulatory authorities, and national pharmacovigilance centres around the world to raise awareness of medication safety and encourage reporting of suspected adverse drug reactions/adverse events following immunisation (ADR/AEFI).

Location/place: 
Online
Date: 
Monday, 7 November 2022 to Sunday, 13 November 2022

PENGUMUMAN: GARIS PANDUAN KELULUSAN PENGIKLANAN PRODUK BERDAFTAR

Date: 15 October 2023 - 5:21am

Garis Panduan ini adalah digunakan sebagai rujukan/panduan tentang perkara-perkara yang harus dipatuhi dalam merangka iklan produk ubat berdaftar untuk kelulusan Lembaga Iklan Ubat. Garis Panduan ini akan mengganti Garis Panduan Pengiklanan Ubat dan Produk Perubatan kepada Orang Ramai. Tarikh penguatkuasaan garis panduan ini adalah pada 1 Oktober 2022.  

Sekiranya tuan/puan mempunyai sebarang pertanyaan lanjut, sila hubungi Sekretariat Lembaga Iklan Ubat di talian 03-78413200 atau melalui emel liu@moh.gov.my.
 

Medicine Advertisements Board (MAB) Guidelines And Policy

Date: 12 February 2026 - 8:25am

These Guidelines are intended to complement the provisions of the Medicines (Advertisement and Sale) Act 1956 (Revised 1983) and the Medicine Advertisements Board Regulations 1976.

Advertisements include any notice, circular, report, commentary, pamphlet, label, wrapper or other document, and any announcement made orally or by any means of producing or transmitting light or sound.

English

Garis Panduan Peminjaman Ubat-ubatan oleh Hospital/Klinik Perubatan Swasta dari Hospital di bawah KKM Semasa Krisis Bekalan Ubat-ubatan di Pasaran Malaysia

Date: 15 October 2023 - 5:22am

Garis panduan ini bertujuan untuk menguatkuasakan pemakaian Panduan Peminjaman Ubat-ubatan oleh hospital/Klinik Perubatan Swasta dari Hospital di bawah Kementerian Kesihatan Malaysia (KKM) semasa Krisis Bekalan Ubat-ubatan di Pasaran Malaysia.

Panduan ini adalah untuk rujukan mana-mana Pengamal Perubatan Swasta dari sesebuah hospital atau klinik perubatan swasta yang berdaftar di bawah Akta Kemudahan dan Perkhidmatan Jagaan Kesihatan Swasta 1998 [Akta 586] yang ingin membuat peminjaman bekalan ubat-ubatan berkaitan isu krisis bekalan ubat di pasaran Malaysia.

English

Guidelines for Authors – Journal of Pharmacy Quality Improvement Initiatives (PharmQIIs)

Date: 2 July 2024 - 7:50am

The Journal of Pharmacy Quality Improvement Initiatives (PharmQIIs) is a peer-reviewed journal published by the Pharmaceutical Services Programme (PSP), Ministry of Health Malaysia (MOH) since 2022. PharmQIIs is set to publish manuscripts derived from Quality Improvement Initiatives (QIIs) that are conducted in Quality Improvement Reports (QIR) format.

Medicine Prices Monitoring Survey in Malaysia 2020

Date: 8 March 2022 - 7:58am

Medicine Prices Monitoring Survey in Malaysia / Kajian Pemantauan Harga Ubat (KPHU) is a commitment of the Pharmaceutical Services Program (PSP) to provide comprehensive information on the availability, price and affordability of medicines in Malaysia. The study conducted since 2006 requires cooperation between Malaysia's public and private healthcare sectors. The selection of facilities and medicines was based on the World Health Organization (WHO) and Health Action International (HAI) guidelines.

English

Clients' Charter Achievement 2022

Date: 15 October 2023 - 5:22am

CLIENTS' CHARTER ACHIEVEMENT

January - May 2022

 

Pages